Capitolis Liquid Global Markets LLC Has $20.25 Million Holdings in Abbott Laboratories (NYSE:ABT)

Capitolis Liquid Global Markets LLC decreased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 64.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 179,000 shares of the healthcare product maker's stock after selling 321,000 shares during the quarter. Capitolis Liquid Global Markets LLC's holdings in Abbott Laboratories were worth $20,247,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its holdings in shares of Abbott Laboratories by 52.6% during the 4th quarter. Nordea Investment Management AB now owns 280,090 shares of the healthcare product maker's stock valued at $31,712,000 after acquiring an additional 96,567 shares during the last quarter. Pensionfund Sabic acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $2,828,000. CWA Asset Management Group LLC lifted its position in shares of Abbott Laboratories by 8.9% during the 4th quarter. CWA Asset Management Group LLC now owns 9,970 shares of the healthcare product maker's stock worth $1,128,000 after purchasing an additional 811 shares during the last quarter. Boltwood Capital Management grew its holdings in Abbott Laboratories by 0.5% in the 4th quarter. Boltwood Capital Management now owns 21,940 shares of the healthcare product maker's stock valued at $2,482,000 after buying an additional 119 shares during the last quarter. Finally, Capital Market Strategies LLC lifted its holdings in shares of Abbott Laboratories by 3.5% during the fourth quarter. Capital Market Strategies LLC now owns 5,985 shares of the healthcare product maker's stock worth $677,000 after buying an additional 200 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 949 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $131,123.33. Following the sale, the executive vice president now directly owns 74,381 shares of the company's stock, valued at approximately $10,277,222.77. This represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the transaction, the director now directly owns 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This trade represents a 7.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 95,278 shares of company stock valued at $12,745,859 in the last three months. 0.46% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Royal Bank of Canada increased their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Thursday, April 17th. Barclays upped their price target on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a report on Thursday, April 17th. Morgan Stanley boosted their price objective on Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a research report on Thursday, April 17th. StockNews.com lowered shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 12th. Finally, Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research report on Tuesday, January 28th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $142.59.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $132.52 on Tuesday. The business has a 50-day moving average of $130.14 and a 200-day moving average of $123.08. The firm has a market capitalization of $230.56 billion, a P/E ratio of 17.32, a PEG ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. On average, equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.78%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories's payout ratio is 30.61%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.